Biotech startup Acrannolife Genomics has received significant backing from the Government of India to scale up manufacturing of its indigenous in-vitro diagnostic (IVD) kits. The support, provided through a flagship scheme for medical devices and diagnostics, aims to boost domestic production of affordable, high-quality IVD kits for critical tests including infectious diseases, oncology markers, cardiac biomarkers, and hormonal assays reducing import dependence and strengthening India’s self-reliance in diagnostics.
Glimpse:
The central government’s approval includes financial incentives, priority access to manufacturing infrastructure, expedited regulatory clearances, and support for technology validation under the PLI scheme for medical devices. Acrannolife will expand its production capacity for rapid antigen, antibody, molecular (PCR-based), and point-of-care IVD kits, targeting both domestic public and private labs as well as export markets. The initiative is expected to create hundreds of skilled jobs, lower testing costs, and enhance availability of Made-in-India diagnostics for high-burden conditions.
Acrannolife Genomics, a Bengaluru-based biotech startup specializing in indigenous in-vitro diagnostic (IVD) kits, has secured substantial support from the Government of India to scale its manufacturing capabilities. The approval, granted under the Production Linked Incentive (PLI) scheme for medical devices and diagnostics, was announced on February 27, 2026, and marks a key milestone in India’s push to achieve self-reliance in critical healthcare technologies. The government backing includes financial incentives, access to dedicated manufacturing infrastructure, expedited CDSCO regulatory clearances, and technical assistance for large-scale production and quality certification.
Acrannolife’s portfolio covers a wide range of IVD kits, including rapid antigen and antibody tests for infectious diseases, molecular diagnostics (PCR-based) for COVID-19, TB, and other pathogens, oncology biomarkers, cardiac panels, hormonal assays, and point-of-care devices. The company has already achieved commercial success with several Made-in-India kits that offer high sensitivity and specificity at significantly lower costs than imported alternatives. With the new support, Acrannolife will expand its GMP-compliant manufacturing facility in Bengaluru, install high-throughput automated production lines, and ramp up output to meet growing demand from government labs, private diagnostic chains, hospitals, and export markets in Southeast Asia and Africa.
The initiative directly addresses India’s heavy reliance on imported IVD kits, which account for over 70–80% of the market in many critical segments. By scaling local production, Acrannolife aims to reduce costs, shorten supply chains, ensure faster availability during outbreaks, and support national programs like the National TB Elimination Programme and universal screening for non-communicable diseases. The company has committed to maintaining rigorous quality standards, pursuing international certifications (CE Mark, WHO prequalification), and partnering with public health agencies for large-scale validation and deployment.
Government officials highlighted that Acrannolife’s selection under the PLI scheme reflects confidence in its technology, manufacturing readiness, and potential to contribute to India’s goal of becoming a global leader in affordable diagnostics. The startup will also benefit from priority access to testing facilities at AMTZ Visakhapatnam and other government-supported centres for performance evaluation and regulatory support. The expansion is expected to create hundreds of high-skill jobs in R&D, production, and quality assurance while strengthening India’s position in the rapidly growing $10+ billion domestic IVD market.
This development underscores the government’s continued focus on fostering indigenous innovation in medical devices and diagnostics, with several other startups and manufacturers also benefiting from similar incentives to build a robust, self-reliant ecosystem capable of meeting both domestic needs and global demand.
“Scaling indigenous IVD manufacturing is critical for India’s health security. With government backing, we are ready to deliver world-class diagnostic kits that are faster, more affordable, and Made in India for the world.”
By
HB Team
